Skip to content
DataLookout
Menu

NCT07474649

A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 7 versions: 7 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened
    • Start date changed from estimate of Sep 30, 2026 to Sep 14, 2026
    • Site details revised at 12 of 12 sites
  2. Minor Site contacts updated at 7 of 12 sites
  3. Notable Start date: Aug 15, 2026 to Sep 30, 2026
    • Eligibility criteria expanded, about 8 words
    • Secondary endpoints: details revised at 1 of 16 entries
    • Study description expanded, about 6 words
  4. Minor Trial sites expanded: 0 → 12 locations
    • Start date: Jul 31, 2026 to Aug 15, 2026
    v4
  5. Notable Start date: Jun 1, 2026 to Jul 31, 2026v3
  6. Notable Lead sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company to Daiichi Sankyo
    • Secondary endpoints: details revised at 1 of 16 entries
    v2
  7. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Annualised change in percentage plaque burden (Δ%PB)
Timeframe: Baseline up to 12 months

Secondary (16)

Key Secondary: Annualised change in normalised non-calcified plaque volume (PV)
Percentage of participants with regression in normalised total plaque volume (TPV), normalised non-calcified PV, and normalised low attenuation PV at EoT (i.e., ΔPV and Δnon-calcified PV, and Δlow-attenuation PV)
Change in the absolute Agatston coronary artery calcium (CAC) score
Annualised ΔTotal Plaque Volume (TPV)
Percentage of participants with regression in TPV (i.e., negative ΔTPV)
Show 11 moreShow less
Absolute annualised change in fractional flow reserve derived from computed tomography (FFRCT) of the vessel with the lowest FFR at Baseline
Absolute annualised change in FFRCT of the average of 3 main epicardial coronary arteries (left anterior descending artery [LAD], circumflex artery [Cx], right coronary artery [RCA])
Mean absolute changes in atherosclerosis-related biomarker total cholesterol
Mean absolute changes in atherosclerosis-related biomarker low-density lipoprotein cholesterol (LDL-C)
Mean absolute changes in atherosclerosis-related biomarker high-density lipoprotein cholesterol (HDL-C)
Mean absolute changes in atherosclerosis-related biomarker non-high-density lipoprotein cholesterol (non-HDL-C)
Mean absolute changes in atherosclerosis-related biomarkers lipoprotein a (Lp(a)) and apolipoprotein B (apoB)
Mean absolute changes in atherosclerosis-related biomarker high-sensitive C reactive protein (hs-CRP)
Annualised changes in Framingham steatosis index (FSI) and fibrosis-4 (Fib-4)
Cumulative incidence of adverse events (AEs) under triple therapy during the trial
Rate of treatment discontinuation during the trial

Arms and interventions

Bempedoic acid (BA)/ezetimibe (EZE) fixed dose combination (FDC) with rosuvastatin or atorvastatinExperimental

Treatment-naïve participants with coronary atherosclerosis and primary non-familial hypercholesterolaemia or mixed dyslipidaemia who will receive daily treatment with BA/EZE FDC, together with either 20 mg rosuvastatin or 40 mg atorvastatin.

Drugs: Bempedoic acid, Ezetimibe, Rosuvastatin, Atorvastatin

Sites

12 sites in 3 countries

Germany 4, Italy 4, Spain 4